Zantac Heartburn Medication
In October 2019, a class-action lawsuit was filed against Sanofi-Aventis U.S., Sanofi US Services, Chattem, Inc., and Boehringer Ingelheim Pharmaceuticals for allegedly failing to disclose that the over-the-counter heartburn medication Zantac exposes users to unsafe levels of the carcinogen N-Nitrosodimethylamine (NDMA). (Dimesky et al v. Sanofi-Aventis U.S., LLC, Sanofi US Services Inc., Chattem, Inc., and Boehringer Ingelheim Pharmaceuticals, Inc., Case No. 19-cv-1517, D. CT.)
Class-Action Tracker
The Latest
CATrends: Unscented Deodorants and Antiperspirants
Lawsuits allege marketing doesn’t pass the smell test.
HydroJug’s Heat-Retention Claims
Can these bottles really keep drinks hot for up to six hours?
With Personalized Pricing, Disclosure Is a Start, But Not a Finish Line
TINA.org and other consumer advocates file comment with FTC.
MLMs Are Consistently Leaving Participants Behind
New book explores why MLMs are often associated with harmful outcomes – and what can be done about it.
Bytech America’s Made in USA Claims
Marketing and reality are not in sync.